Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

ProMIS Neurosciences Inc. (T:PMN)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for PMN within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jun 22, 2022 07:00 ET
ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the...
Read full article
Jun 22, 2022 07:00 ET
ProMIS Neurosciences Announces Debt Amendment and Conversion
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.89
--
--
Price to Sales - TTM
1,867.10
10.23
4.28
Price to Book - most recent quarter
12.02
2.02
1.80
Price to Cash Flow per share - TTM
--
--
9.43
Price to Free Cash Flow per share - TTM
--
6.01
18.71
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 15, 2022698,23583,665
May 31, 2022614,570-105,505
May 15, 2022720,07554,408
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

ProMIS Neurosciences, Inc. is a Canada-based development-stage biotechnology company. The Company is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company is focused on the discovery engine, which is based on the use of two complementary algorithms: ProMIS and Collective Coordinates, which are used to predict targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. The Company is focused on developing antibody therapeutics for AD, ALS and PD. The Company has a wholly owned subsidiary is ProMIS Neurosciences (US) Inc. (ProMIS USA).

See business summary

 

Twitter

Search (past week) for $PMN.CA

  • No tweets found